Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10115406 | 1.00 | MAPT (0.48) | MAPTNAMPTCYP2C9TRPV1GRIA2 | |
| SCHEMBL10133522 | 1.00 | MAPT (0.48) | MAPTNAMPTCYP2C9TRPV1GRIA2 | |
| SCHEMBL10115044 | 0.88 | MAPT (0.46) | MAPTNAMPTCYP2C9TRPV1CCR3 | |
| SCHEMBL10133227 | 0.88 | MAPT (0.46) | MAPTNAMPTCYP2C9TRPV1CCR3 | |
| SCHEMBL13204501 | 0.88 | MAPT (0.46) | MAPTNAMPTCYP2C9TRPV1CCR3 | |
| SCHEMBL12881987 | 0.86 | MAPT (0.48) | MAPTNAMPTCYP2C9TRPV1ALDH1A1 | |
| SCHEMBL13204340 | 0.86 | MAPT (0.48) | MAPTNAMPTCYP2C9TRPV1ALDH1A1 | |
| SCHEMBL10133231 | 0.82 | MAPT (0.48) | MAPTNAMPTCYP2C9TRPV1ALDH1A1 | |
| SCHEMBL10114821 | 0.82 | MAPT (0.48) | MAPTNAMPTCYP2C9TRPV1ALDH1A1 | |
| SCHEMBL10113352 | 0.78 | MAPT (0.48) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | MAPT 3602/4885NAMPT 2678/4885CYP2C9 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.